Cetuximab injection

DRUG5 trials

Sponsors

Dragonboat Biopharmaceutical Company Limited, Cliniques universitaires Saint-Luc- Université Catholique de Louvain, Shanghai Miracogen Inc., Shanghai Institute Of Biological Products

Conditions

Colorectal CancerColorectal Neoplasms, MalignantHead and Neck Squamous Cell CarcinomaHealthy VolunteersSquamous Cell Carcinoma of the Head and Neck

Phase 1

A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC

Dragonboat Biopharmaceutical Company LimitedColorectal Cancer

Start: 2018-07-01End: 2019-12-01Updated: 2019-10-31

Clinical Trial to Evaluate Pharmacokinetics,Safety and Immunogenicity of Single Injection of CDP1 to Healthy Volunteers Compared to Erbitux

Dragonboat Biopharmaceutical Company LimitedHealthy Volunteers

Start: 2019-02-27End: 2019-12-30Target: 84Updated: 2019-03-20

Phase 2

Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer

Cliniques universitaires Saint-Luc- Université Catholique de LouvainColorectal Neoplasms, Malignant

Start: 2018-10-03End: 2023-12-31Target: 59Updated: 2020-10-22

Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma

RecruitingNCT06194656

Shanghai Institute Of Biological ProductsHead and Neck Squamous Cell Carcinoma

Start: 2024-09-27End: 2026-07-30Target: 81Updated: 2026-01-16

Phase 3

A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN

Shanghai Miracogen Inc.Squamous Cell Carcinoma of the Head and Neck

Start: 2023-03-31End: 2025-12-31Target: 180Updated: 2023-03-02

Related Papers

Impact of the tumor immune contexture in microsatellite-stable metastatic colorectal cancer treated with avelumab, cetuximab, and irinotecan.

2025-06-241 citations

Interim analysis of the phase II AVETUXIRI trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2022-06-0110 citations

Interim analysis of the AVETUXIRI Trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC)—A proof of concept, open-label, nonrandomized phase IIa study.

Journal of Clinical Oncology2021-01-2029 citations